Targeted therapies for cutaneous melanoma

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Melanoma historically shows resistance to cytotoxic therapies, limiting advanced disease treatment options.
• Recent advances in understanding melanoma driver mutations, especially in the mitogen-activated protein kinase (MAPK) pathway, have revolutionized treatment approaches.

Purpose of the Study:

• To review the efficacy of targeted therapies in melanoma based on specific genetic mutations.
• To highlight the impact of improved understanding of molecular pathways on treatment outcomes.

Main Methods:

• Review of clinical trial data and scientific literature on targeted melanoma therapies.
• Analysis of efficacy data for RAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib) in BRAF V600 mutated melanoma.
• Examination of emerging data for MEK inhibitors in NRAS-mutated melanoma and KIT inhibitors in KIT-driven melanoma.

Main Results:

• Selective RAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib) demonstrate significant survival benefits in cutaneous melanomas with BRAF V600 mutations.
• Early evidence suggests efficacy of MEK inhibitors in NRAS-mutated melanomas.
• KIT inhibitors show promise for melanomas with activated KIT receptor signaling.

Conclusions:

• Targeted therapies have transformed the treatment landscape for advanced melanoma, offering effective options for previously refractory disease.
• Understanding specific driver mutations, such as BRAF V600, NRAS, and KIT, is crucial for selecting effective targeted treatments.
• Continued research into molecular pathways and targeted agents promises further improvements in melanoma patient outcomes.